trending Market Intelligence /marketintelligence/en/news-insights/trending/mQoI77q65pXW4FK3BPHvFQ2 content esgSubNav
In This List

US FDA approves Teva's drug for chorea linked to Huntington's disease

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


US FDA approves Teva's drug for chorea linked to Huntington's disease

The U.S. FDA approved Teva Pharmaceutical Industries Ltd.'s AUSTEDO tablets for the treatment of chorea associated with Huntington's disease.

The FDA approval was based on results from a phase 3 study to assess the safety and efficacy of the drug in reducing chorea in patients with the disease.

Previously, the agency granted the drug an orphan drug designation in 2014.